Trial Profile
A study evaluating clinical and economic impact of Promixin in patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Nov 2017
Price :
$35
*
At a glance
- Drugs Colistimethate sodium (Primary)
- Indications Bronchiectasis; Pseudomonal infections
- Focus Therapeutic Use
- 15 Nov 2017 New trial record